EIT Health promotes entrepreneurship and innovates in healthy living and active ageing, with the aim to improve quality of life and healthcare across Europe.
EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the foundations of healthcare and thus promote the future conditions for healthier living and wellbeing of people across Europe. EIT Health is leveraging the expertise of more than 140 leading organizations spanning key areas of healthcare such as Pharma, MedTech, Payers, Research Institutions and Universities. EIT Health offers best-in-class research capabilities, higher education and business expertise. With a budget of €2 billion over the next decade, it will purposefully invest in Europe’s best entrepreneurial talents and creative minds to foster the development and commercialization of smart product and service solutions in the health sector, addressing the challenges imposed by demographic change and ageing societies. Projects, Education activities and Business Creation activities are financed via in-kind contributions from participating organisations and by funding requested from The EIT. More Information about EIT Health, its members and activities can be found on www.eithealth.eu
Description: Johnson & Johnson Innovation LLC is working to accelerate scientific innovation at all stages of development worldwide to deliver cutting-edge solutions that solve unmet needs for patients. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to the broad resources of the Johnson & Johnson Family of Companies across the Pharmaceutical, Medical Devices and Consumer healthcare segments. This includes access to dealmakers, through the innovation centers located in global life science hot spots and Johnson & Johnson Innovation – Janssen Business Development; venture investment, through Johnson & Johnson Innovation – JJDC; company incubation, through Johnson & Johnson Innovation, JLABS; as well as R&D, manufacturing and commercialization expertise across all three segments.
As part of the strategic collaboration agreement with Karolinska Institutet Holding Ab, Johnson & Johnson Innovation has offices in the Science Park, building Gamma, 7th floor.
Cadila Pharmaceuticals Sweden AB is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the World.
Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, biotechnology products, plant tissue culture and more than 38 APIs and intermediates. In the services realm, our offering includes Pre-Clinical and Clinical Research as well as Contract Manufacturing.
We have scientific collaborations with leading Swedish companies for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.
The Swedish office has been set up to ensure success of ongoing and future collaborations between Swedish companies and institutions, and our Indian organization. We encourage regional researchers and companies to get in touch with us to discuss potential collaborations or our service offerings.
Karolinska Institutet Innovations AB (KIAB) is the first commercial instance in the overall innovation system. Every year hundreds of research projects are reviewed and evaluated by KIAB´s carefully selected experts. Projects with a possible commercial potential are offered professional support all the way through the important development process.
From idea to business-for public health and welfare. A large part of the innovation system at Karolinska Institutet is managed by Karolinska Institutet Holding AB
Karolinska Institutet places great value on a dynamic interaction between the academic and the commercial sectors – for mutual benefits and general improvement for the whole society.
To enable professional evaluation, development and commercialisation of interesting innovations in Life Science and Medical Technology an overall innovationsystem has been created – KI Innovation.
This unique system develops research ideas from both Swedish and other Nordic universities.
Some of the main tasks for KI Holding is to manage stocks in research-and development companies, establish joint ownership in promising enterprises, offer good infrastructure for newly started companies and to provide administrative, legal and financial services for around 45 companies.
Karolinska Institutet Holding AB, creates the possibility for KI to act commercially. This means that KI Holding can take risks and also is allowed to make profits – as opposed to state-owned Karolinska Institutet.
KI Holding operates mainly through the wholly owned subsidiary companies: Karolinska Instututet Housing AB, Karolinska Institutet Innovations AB, Karolinska Institutet Science Park AB and Karolinska Institutet University Press AB
KI Holding owns 16 percent of the shares in the investment company Karolinska Development AB, which has a portfolio of around 40 companies in the Life Science sector.
KI Holding also owns 25 percent of the shares in Biocelex Oy, an innovation- and business development company based in Turku, Finland.
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.
Karolinska Development’s flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients – this being an important value enhancing step.
Today, the portfolio consists of over 35 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women’s health and diseases that affect the central nervous system. www.karolinskadevelopment.com
Flemingsberg Science was established 2011 by the Karolinska Institute, KTH, Södertörn University College, Stockholm County Council and the local communities of Huddinge and Botkyrka, to enhance the innovation and business community of Flemingsberg.
Our main activities are centered around the concept of business architecture. The Business Architecture project starts with real, unmet needs in health care, as defined by patients and clinicians. These needs are found by our business architects, walking the corridors of hospitals, talking to people. An assessment of each need in terms of value creation of solving the problem, and the possibility to find solutions and business models, is done. Based on these assessments a limited number of needs are selected as starting point for business creation, including setting a development team with clinicians, academics and business people, checking IP & freedom to operate, the international business potential etcetera. Our output is a well-defined business case with a substantial interest from the clinical world, a substantial value creation, one or more solution ideas, a validated market and above all, a team who are willing to invest time and/or money to carry on. The taker of the project might be an entrepreneurial team building a start-up, or an existing company picking up a new product.